Monitoring additive manufacturing based products in clinical trials

Yorgos Marinakis, Rainer Harms, Steven Thomas Walsh

    Research output: Contribution to journalArticleProfessional

    Abstract

    Under U.S. federal regulation 31 CFR §312, medical interventions must report on a series of clinical trials phases before being submitted for approval for release to the U.S. market. Clinical trials are now being performed on medical interventions that were constructed through additive manufacturing.
    Serious adverse events (SAEs) in clinical trials would be the first indicator of problems in the application of additive manufacturing to medical interventions. Techniques for the visual display of aggregates of reports from clinical trials involving additive manufacturing will become more important as data becomes Big Data. Novel methods are needed for economically displaying clinical
    trials Big Data to industry watchers, investors and other interested parties. Aggregate indicators of additive manufacturing-based clinical trials SAEs would be of particular interest to industry watchers, investors and policy makers. In the present study, indexes are constructed comprising percents of interventional clinical trials reporting SAEs from 1997–2014, aggregated by the year in which the study commenced. The present research falls within the discipline of biomedical informatics.
    Original languageEnglish
    Article number034001
    Number of pages7
    JournalTranslational materials research
    Volume4
    DOIs
    Publication statusPublished - 26 Sep 2017

    Fingerprint Dive into the research topics of 'Monitoring additive manufacturing based products in clinical trials'. Together they form a unique fingerprint.

  • Cite this